Stabilization of Nrf2 leading to HO-1 activation protects against zinc oxide nanoparticles-induced endothelial cell death
With the abundant production and wide application of zinc oxide nanoparticles (ZnONPs), the potential health risks of ZnONPs have raised serious concerns. Oxidative stress is recognized as the most important outcome of the toxicity induced by ZnONPs. The Nrf2-Keap1 system and its downstream antioxid...
Saved in:
Published in | Nanotoxicology Vol. 15; no. 6; pp. 779 - 797 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Taylor & Francis
03.07.2021
Taylor & Francis Ltd |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | With the abundant production and wide application of zinc oxide nanoparticles (ZnONPs), the potential health risks of ZnONPs have raised serious concerns. Oxidative stress is recognized as the most important outcome of the toxicity induced by ZnONPs. The Nrf2-Keap1 system and its downstream antioxidative genes are the fundamental protective mechanisms for redox hemeostasis. However, the detailed mechanisms of Nrf2 activation in ZnONPs-treated endothelial cells and murine blood vessels have yet to be elucidated. Herein, we show that Nrf2 was activated and played a negative role in cell death induced by ZnONPs. Moreover, we demonstrate that HO-1 was the most extensively upregulated antioxidative gene-activated by Nrf2. Forced overexpression of HO-1, pharmacological activation of HO-1 with the agonists RTA-408 (omaveloxolone, an FDA-approved drug) and RTA-402 repressed cell death, and treatment with HO-1 antagonist SnPP exacerbated the cell death. Importantly, loss of HO-1 diminished the cytoprotective role induced by Nrf2 in ZnONPs-treated HUVEC cells, indicating that the Nrf2-HO-1 axis was the crucial regulatory mechanism for the antioxidative response in the context of ZnONPs-induced endothelial damage. Mechanistically, we demonstrate that the p62-Keap1 axis was not involved in the activation of Nrf2. Intriguingly, the degradation half-life of Nrf2 in HUVEC cells was increased from less than 1 h under quiescent conditions to approximately 6 h under ZnONPs treatment condition; moreover, ZnONPs treatment induced activation of Nrf2/HO-1 and accumulation of ubiquitin in the aorta ventralis of mouse, suggesting that the ubiquitin-proteasome system had been perturbed, which subsequently led to the stabilization of Nrf2 and activation of HO-1. This study might contribute to a better understanding of ZnONPs-associated toxicity. |
---|---|
AbstractList | With the abundant production and wide application of zinc oxide nanoparticles (ZnONPs), the potential health risks of ZnONPs have raised serious concerns. Oxidative stress is recognized as the most important outcome of the toxicity induced by ZnONPs. The Nrf2-Keap1 system and its downstream antioxidative genes are the fundamental protective mechanisms for redox hemeostasis. However, the detailed mechanisms of Nrf2 activation in ZnONPs-treated endothelial cells and murine blood vessels have yet to be elucidated. Herein, we show that Nrf2 was activated and played a negative role in cell death induced by ZnONPs. Moreover, we demonstrate that HO-1 was the most extensively upregulated antioxidative gene-activated by Nrf2. Forced overexpression of HO-1, pharmacological activation of HO-1 with the agonists RTA-408 (omaveloxolone, an FDA-approved drug) and RTA-402 repressed cell death, and treatment with HO-1 antagonist SnPP exacerbated the cell death. Importantly, loss of HO-1 diminished the cytoprotective role induced by Nrf2 in ZnONPs-treated HUVEC cells, indicating that the Nrf2-HO-1 axis was the crucial regulatory mechanism for the antioxidative response in the context of ZnONPs-induced endothelial damage. Mechanistically, we demonstrate that the p62-Keap1 axis was not involved in the activation of Nrf2. Intriguingly, the degradation half-life of Nrf2 in HUVEC cells was increased from less than 1 h under quiescent conditions to approximately 6 h under ZnONPs treatment condition; moreover, ZnONPs treatment induced activation of Nrf2/HO-1 and accumulation of ubiquitin in the aorta ventralis of mouse, suggesting that the ubiquitin-proteasome system had been perturbed, which subsequently led to the stabilization of Nrf2 and activation of HO-1. This study might contribute to a better understanding of ZnONPs-associated toxicity. With the abundant production and wide application of zinc oxide nanoparticles (ZnONPs), the potential health risks of ZnONPs have raised serious concerns. Oxidative stress is recognized as the most important outcome of the toxicity induced by ZnONPs. The Nrf2-Keap1 system and its downstream antioxidative genes are the fundamental protective mechanisms for redox hemeostasis. However, the detailed mechanisms of Nrf2 activation in ZnONPs-treated endothelial cells and murine blood vessels have yet to be elucidated. Herein, we show that Nrf2 was activated and played a negative role in cell death induced by ZnONPs. Moreover, we demonstrate that HO-1 was the most extensively upregulated antioxidative gene-activated by Nrf2. Forced overexpression of HO-1, pharmacological activation of HO-1 with the agonists RTA-408 (omaveloxolone, an FDA-approved drug) and RTA-402 repressed cell death, and treatment with HO-1 antagonist SnPP exacerbated the cell death. Importantly, loss of HO-1 diminished the cytoprotective role induced by Nrf2 in ZnONPs-treated HUVEC cells, indicating that the Nrf2-HO-1 axis was the crucial regulatory mechanism for the antioxidative response in the context of ZnONPs-induced endothelial damage. Mechanistically, we demonstrate that the p62-Keap1 axis was not involved in the activation of Nrf2. Intriguingly, the degradation half-life of Nrf2 in HUVEC cells was increased from less than 1 h under quiescent conditions to approximately 6 h under ZnONPs treatment condition; moreover, ZnONPs treatment induced activation of Nrf2/HO-1 and accumulation of ubiquitin in the aorta ventralis of mouse, suggesting that the ubiquitin-proteasome system had been perturbed, which subsequently led to the stabilization of Nrf2 and activation of HO-1. This study might contribute to a better understanding of ZnONPs-associated toxicity.With the abundant production and wide application of zinc oxide nanoparticles (ZnONPs), the potential health risks of ZnONPs have raised serious concerns. Oxidative stress is recognized as the most important outcome of the toxicity induced by ZnONPs. The Nrf2-Keap1 system and its downstream antioxidative genes are the fundamental protective mechanisms for redox hemeostasis. However, the detailed mechanisms of Nrf2 activation in ZnONPs-treated endothelial cells and murine blood vessels have yet to be elucidated. Herein, we show that Nrf2 was activated and played a negative role in cell death induced by ZnONPs. Moreover, we demonstrate that HO-1 was the most extensively upregulated antioxidative gene-activated by Nrf2. Forced overexpression of HO-1, pharmacological activation of HO-1 with the agonists RTA-408 (omaveloxolone, an FDA-approved drug) and RTA-402 repressed cell death, and treatment with HO-1 antagonist SnPP exacerbated the cell death. Importantly, loss of HO-1 diminished the cytoprotective role induced by Nrf2 in ZnONPs-treated HUVEC cells, indicating that the Nrf2-HO-1 axis was the crucial regulatory mechanism for the antioxidative response in the context of ZnONPs-induced endothelial damage. Mechanistically, we demonstrate that the p62-Keap1 axis was not involved in the activation of Nrf2. Intriguingly, the degradation half-life of Nrf2 in HUVEC cells was increased from less than 1 h under quiescent conditions to approximately 6 h under ZnONPs treatment condition; moreover, ZnONPs treatment induced activation of Nrf2/HO-1 and accumulation of ubiquitin in the aorta ventralis of mouse, suggesting that the ubiquitin-proteasome system had been perturbed, which subsequently led to the stabilization of Nrf2 and activation of HO-1. This study might contribute to a better understanding of ZnONPs-associated toxicity. |
Author | Zou, Liyong Cheng, Shuqun Zhang, Longbin Zou, Zhen Qin, Zhexue Qin, Xia Chen, Chengzhi Jiang, Xuejun Zhang, Jun |
Author_xml | – sequence: 1 givenname: Longbin surname: Zhang fullname: Zhang, Longbin organization: Institute of Life Sciences, Chongqing Medical University – sequence: 2 givenname: Liyong surname: Zou fullname: Zou, Liyong organization: Institute of Life Sciences, Chongqing Medical University – sequence: 3 givenname: Xuejun surname: Jiang fullname: Jiang, Xuejun organization: Center of Experimental Teaching for Public Health, Experimental Teaching and Management Center, Chongqing Medical University – sequence: 4 givenname: Shuqun surname: Cheng fullname: Cheng, Shuqun organization: Department of Occupational and Environmental Health, School of Public Health and Management, Chongqing Medical University – sequence: 5 givenname: Jun surname: Zhang fullname: Zhang, Jun organization: Institute of Life Sciences, Chongqing Medical University – sequence: 6 givenname: Xia surname: Qin fullname: Qin, Xia organization: Department of Pharmacy, The First Affiliated Hospital of Chongqing Medical University – sequence: 7 givenname: Zhexue surname: Qin fullname: Qin, Zhexue organization: Institute of Cardiovascular Diseases of PLA, the Second Affiliated Hospital, Third Military Medical University (Army Medical University) – sequence: 8 givenname: Chengzhi orcidid: 0000-0002-1087-4911 surname: Chen fullname: Chen, Chengzhi organization: Dongsheng Lung-Brain Disease Joint Lab, Chongqing Medical University – sequence: 9 givenname: Zhen orcidid: 0000-0002-1651-591X surname: Zou fullname: Zou, Zhen organization: Dongsheng Lung-Brain Disease Joint Lab, Chongqing Medical University |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33971103$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkU9vEzEQxS1URP_ARwBZ4sJlg71e78biQlUVilTRA3C2Jva4deXYwfYC6afvLkkuPcBprNHvjZ_eOyVHMUUk5DVnC86W7D0fOiGFYouWtXzBFVdCsGfkZN43smPd0eE9QcfktJR7xmTf9vwFORZCDZwzcUK23yqsfPAPUH2KNDn6NbuWBgTr4y2tiV7dNJyCqf7XDtnkVNHUQuEWfCyVPvhoaPrjLdIIMW0gV28ClsZHOxq0FKNN9Q6Dh0ANhkAtQr17SZ47CAVf7ecZ-fHp8vvFVXN98_nLxfl1YyQbasOlAmMNmp4B9ii5cVwtUTGrGHcgTCeUBCes44z1HQ6yE6sBWzYovpJTRGfk3e7uZPzniKXqtS-zDYiYxqJb2cq-552c0bdP0Ps05ji5m6ie8X45LNVEvdlT42qNVm-yX0Pe6kOoE_BhB5icSsnotPH1b3g1gw-aMz1XqA8V6rlCva9wUssn6sMH_9N93Ol8dCmv4XfKweoK25CyyxCNL1r8-8Qj9dKx7w |
CitedBy_id | crossref_primary_10_1002_advs_202106049 crossref_primary_10_1016_j_jtemb_2025_127618 crossref_primary_10_3389_ftox_2022_974429 crossref_primary_10_1016_j_jhazmat_2024_134440 crossref_primary_10_1039_D3BM00271C crossref_primary_10_1165_rcmb_2021_0515OC crossref_primary_10_1080_15376516_2024_2431687 crossref_primary_10_1016_j_etap_2024_104469 crossref_primary_10_1186_s12951_022_01486_7 crossref_primary_10_3390_molecules27185755 crossref_primary_10_1016_j_toxlet_2022_11_002 crossref_primary_10_33549_physiolres_935330 crossref_primary_10_3390_v14122799 crossref_primary_10_2147_IJN_S386240 crossref_primary_10_1007_s11356_022_19821_8 crossref_primary_10_1016_j_jep_2023_117619 crossref_primary_10_3389_fphar_2024_1360177 |
Cites_doi | 10.1172/JCI60331 10.1016/j.drudis.2017.08.006 10.1038/cddis.2017.337 10.1166/jbn.2019.2696 10.1021/nn800511k 10.1007/s00395-014-0450-9 10.1186/1743-8977-8-27 10.1038/srep43126 10.1016/j.toxlet.2017.12.025 10.1016/j.cell.2012.03.042 10.2147/IJN.S224179 10.1002/med.21396 10.1155/2018/1062562 10.5402/2012/372505 10.1161/CIRCRESAHA.116.306588 10.1038/ncb2021 10.1146/annurev-pharmtox-011112-140320 10.1016/j.cell.2013.12.010 10.3390/nano7110354 10.1038/nri2171 10.1093/nar/gkaa631 10.1080/17435390.2018.1513094 10.1242/jcs.222836 10.1016/S0009-2614(02)01106-5 10.1080/17435390.2018.1537409 10.1021/la104825u 10.1146/annurev.pharmtox.010909.105600 10.1089/ars.2017.7342 10.1016/j.freeradbiomed.2018.09.032 10.1146/annurev.pharmtox.46.120604.141046 10.1289/EHP424 10.1002/smll.202000963 10.1126/science.1114397 10.2147/NSA.S23932 10.1074/jbc.M209195200 10.1186/s12989-019-0328-y 10.1021/acsami.7b11219 10.1128/MCB.26.1.221-229.2006 10.3109/10408444.2015.1137864 10.1212/WNL.0000000000008861 10.2147/IJN.S250367 10.1155/2017/9237263 10.2147/IJN.S121956 10.2174/1566524013666131111130058 10.3390/molecules190710074 10.1080/15548627.2021.1911016 10.1002/adma.201301732 |
ContentType | Journal Article |
Copyright | 2021 Informa UK Limited, trading as Taylor & Francis Group 2021 2021 Informa UK Limited, trading as Taylor & Francis Group |
Copyright_xml | – notice: 2021 Informa UK Limited, trading as Taylor & Francis Group 2021 – notice: 2021 Informa UK Limited, trading as Taylor & Francis Group |
DBID | AAYXX CITATION NPM K9. 7X8 |
DOI | 10.1080/17435390.2021.1919330 |
DatabaseName | CrossRef PubMed ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
DatabaseTitle | CrossRef PubMed ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
DatabaseTitleList | PubMed MEDLINE - Academic ProQuest Health & Medical Complete (Alumni) |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1743-5404 |
EndPage | 797 |
ExternalDocumentID | 33971103 10_1080_17435390_2021_1919330 1919330 |
Genre | Research Article Journal Article |
GroupedDBID | --- 00X 0BK 0R~ 123 4.4 53G AALUX AAMIU AAPUL AAQRR ABBKH ABDBF ABEIZ ABJNI ABLIJ ABLKL ABUPF ABXYU ACENM ACGEJ ACIEZ ACPRK ACUHS ADCVX ADXPE AECIN AENEX AEOZL AFRAH AGDLA AGFJD AGRBW AGYJP AIJEM AIRBT AKBVH ALMA_UNASSIGNED_HOLDINGS ALQZU ALYBC BABNJ BLEHA BOHLJ CCCUG CS3 DKSSO DU5 EBD EBS EMOBN ESX F5P H13 HZ~ KRBQP KSSTO KWAYT KYCEM LJTGL M4Z MM. O9- P2P RNANH RVRKI SV3 TBQAZ TDBHL TERGH TFL TFW TUROJ TUS UHWXJ V1S ~1N AAGDL AAYXX ABWVI ADYSH AFRVT AMPGV CITATION NPM K9. TASJS 7X8 |
ID | FETCH-LOGICAL-c507t-159acdcec60ae6e51cf198e90d901fa3c4395af3df10064e7543b7e20791b5353 |
ISSN | 1743-5390 1743-5404 |
IngestDate | Fri Jul 11 01:10:40 EDT 2025 Wed Aug 13 11:15:25 EDT 2025 Wed Feb 19 02:27:36 EST 2025 Thu Apr 24 23:04:55 EDT 2025 Tue Jul 01 03:28:08 EDT 2025 Wed Dec 25 09:07:24 EST 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 6 |
Keywords | ZnONPs ubiquitin-proteasome system HO-1 Nrf2 antioxidative response |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c507t-159acdcec60ae6e51cf198e90d901fa3c4395af3df10064e7543b7e20791b5353 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ORCID | 0000-0002-1651-591X 0000-0002-1087-4911 |
OpenAccessLink | https://figshare.com/articles/journal_contribution/Stabilization_of_Nrf2_leading_to_HO-1_activation_protects_against_zinc_oxide_nanoparticles-induced_endothelial_cell_death/14569280 |
PMID | 33971103 |
PQID | 2560168789 |
PQPubID | 2043362 |
PageCount | 19 |
ParticipantIDs | proquest_miscellaneous_2525661455 pubmed_primary_33971103 proquest_journals_2560168789 informaworld_taylorfrancis_310_1080_17435390_2021_1919330 crossref_citationtrail_10_1080_17435390_2021_1919330 crossref_primary_10_1080_17435390_2021_1919330 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2021-07-03 |
PublicationDateYYYYMMDD | 2021-07-03 |
PublicationDate_xml | – month: 07 year: 2021 text: 2021-07-03 day: 03 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: Abingdon |
PublicationTitle | Nanotoxicology |
PublicationTitleAlternate | Nanotoxicology |
PublicationYear | 2021 |
Publisher | Taylor & Francis Taylor & Francis Ltd |
Publisher_xml | – name: Taylor & Francis – name: Taylor & Francis Ltd |
References | CIT0030 CIT0010 CIT0032 CIT0031 CIT0012 CIT0034 CIT0011 CIT0033 CIT0014 CIT0036 CIT0013 CIT0035 CIT0016 CIT0038 CIT0015 CIT0037 CIT0018 CIT0017 CIT0039 CIT0019 CIT0041 CIT0040 CIT0021 CIT0043 CIT0020 CIT0042 CIT0001 CIT0023 CIT0045 CIT0022 CIT0044 CIT0003 CIT0025 CIT0047 CIT0002 CIT0024 CIT0046 CIT0005 CIT0027 CIT0004 CIT0026 CIT0007 CIT0029 CIT0006 CIT0028 CIT0009 CIT0008 |
References_xml | – ident: CIT0018 doi: 10.1172/JCI60331 – ident: CIT0019 doi: 10.1016/j.drudis.2017.08.006 – ident: CIT0045 doi: 10.1038/cddis.2017.337 – ident: CIT0038 doi: 10.1166/jbn.2019.2696 – ident: CIT0041 doi: 10.1021/nn800511k – ident: CIT0002 doi: 10.1007/s00395-014-0450-9 – ident: CIT0001 doi: 10.1186/1743-8977-8-27 – ident: CIT0012 doi: 10.1038/srep43126 – ident: CIT0035 doi: 10.1016/j.toxlet.2017.12.025 – ident: CIT0003 doi: 10.1016/j.cell.2012.03.042 – ident: CIT0014 doi: 10.2147/IJN.S224179 – ident: CIT0015 doi: 10.1002/med.21396 – ident: CIT0005 doi: 10.1155/2018/1062562 – ident: CIT0032 doi: 10.5402/2012/372505 – ident: CIT0021 doi: 10.1161/CIRCRESAHA.116.306588 – ident: CIT0011 doi: 10.1038/ncb2021 – ident: CIT0016 doi: 10.1146/annurev-pharmtox-011112-140320 – ident: CIT0043 doi: 10.1016/j.cell.2013.12.010 – ident: CIT0009 doi: 10.3390/nano7110354 – ident: CIT0022 doi: 10.1038/nri2171 – ident: CIT0031 doi: 10.1093/nar/gkaa631 – ident: CIT0006 doi: 10.1080/17435390.2018.1513094 – ident: CIT0026 doi: 10.1242/jcs.222836 – ident: CIT0047 doi: 10.1016/S0009-2614(02)01106-5 – ident: CIT0039 doi: 10.1080/17435390.2018.1537409 – ident: CIT0025 doi: 10.1021/la104825u – ident: CIT0004 doi: 10.1146/annurev.pharmtox.010909.105600 – ident: CIT0033 doi: 10.1089/ars.2017.7342 – ident: CIT0044 doi: 10.1016/j.freeradbiomed.2018.09.032 – ident: CIT0007 doi: 10.1146/annurev.pharmtox.46.120604.141046 – ident: CIT0030 doi: 10.1289/EHP424 – ident: CIT0040 doi: 10.1002/smll.202000963 – ident: CIT0020 doi: 10.1126/science.1114397 – ident: CIT0034 doi: 10.2147/NSA.S23932 – ident: CIT0029 doi: 10.1074/jbc.M209195200 – ident: CIT0028 doi: 10.1186/s12989-019-0328-y – ident: CIT0036 doi: 10.1021/acsami.7b11219 – ident: CIT0010 doi: 10.1128/MCB.26.1.221-229.2006 – ident: CIT0013 doi: 10.3109/10408444.2015.1137864 – ident: CIT0017 doi: 10.1212/WNL.0000000000008861 – ident: CIT0024 doi: 10.2147/IJN.S250367 – ident: CIT0027 doi: 10.1155/2017/9237263 – ident: CIT0037 doi: 10.2147/IJN.S121956 – ident: CIT0046 doi: 10.2174/1566524013666131111130058 – ident: CIT0008 doi: 10.3390/molecules190710074 – ident: CIT0023 doi: 10.1080/15548627.2021.1911016 – ident: CIT0042 doi: 10.1002/adma.201301732 |
SSID | ssj0056261 |
Score | 2.3737566 |
Snippet | With the abundant production and wide application of zinc oxide nanoparticles (ZnONPs), the potential health risks of ZnONPs have raised serious concerns.... |
SourceID | proquest pubmed crossref informaworld |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 779 |
SubjectTerms | antioxidative response Aorta Apoptosis Blood vessels Cell activation Cell death Endothelial cells Health risks HO-1 Mortality Nanoparticles Nrf2 NRF2 protein Oxidative stress Proteasomes Regulatory mechanisms (biology) Stabilization Toxicity Ubiquitin ubiquitin-proteasome system Zinc oxide Zinc oxides ZnONPs |
Title | Stabilization of Nrf2 leading to HO-1 activation protects against zinc oxide nanoparticles-induced endothelial cell death |
URI | https://www.tandfonline.com/doi/abs/10.1080/17435390.2021.1919330 https://www.ncbi.nlm.nih.gov/pubmed/33971103 https://www.proquest.com/docview/2560168789 https://www.proquest.com/docview/2525661455 |
Volume | 15 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF5BeuGCeBMoaJFQL66D37GPbWkUoZD24EgRF8veR2tU2dDYEsmvZ8a7dhwR1MLFija7tuX5PPvN551ZQj4yL-S2yDwztUNpejIK4JXKXFPaIUzWXGacoaD_dR5MF96Xpb_sfTHF7JIqG7HN3ryS_7EqtIFdMUv2HyzbnRQa4DfYF45gYTjey8bAFHFt66ajffNb6eBGEE2mCrDK6YVpN-UylPBq6KoMKyO9SnMghsYmL5hR_sq5MIq0gABar5MzIVSvcWmAKDjmaN2gsI4iv8GRM_YpLfjnsoJTsB2BvhOiZ2VxleUdBL-VtZIC1qWeM3H5Tq47L2vxve76nl0LLWZf1z91sxYoHLtZzOr2fCpWQQViqHQDsaetdcR-D3B9rzpW-8384e3V8kg8l-9G1ggvPoL4EzWa7fTWftKfXySTxWyWxOfL-CE5cCCscAbk4OT08-mknbuBDKoKu-3ttTlfofVp72V22MxOrdu_RywNc4mfkMc65KAnyrRPyQNRPCNHl6pm-fqYxtsUvNUxPaKX22rm6-dkvQMyWkqKIKMaZLQqKYKMbkFGW5BRDTKKIKMNyOhekNEeyCiCjDYge0EWk_P4bGrq_TpMBlFFZQIzThlnggVWKgLh20zaUSgiiwPplKnLgPz6qXS5tJEJi7HvudlYONYY3IMPD_clGRRlIV4TGthMuE4GXMlhnseDiPtOKCFciCDAldIbEq997gnTxexxT5WbxNY1b1tzJWiuRJtrSEbdsB-qmstdA6K-UZOqkdGk2vMmce8Ye9giINFOY5U0CkgQjsNoSD50f4NLx6ebFqKssQ_0CnAHgSF5pZDT3a0L8QMwdvfNPUa_JY-27-MhGVS3tXgHFLrK3mvc_wbq0sOG |
linkProvider | EBSCOhost |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Stabilization+of+Nrf2+leading+to+HO-1+activation+protects+against+zinc+oxide+nanoparticles-induced+endothelial+cell+death&rft.jtitle=Nanotoxicology&rft.au=Zhang%2C+Longbin&rft.au=Zou%2C+Liyong&rft.au=Jiang%2C+Xuejun&rft.au=Cheng%2C+Shuqun&rft.date=2021-07-03&rft.issn=1743-5404&rft.eissn=1743-5404&rft.volume=15&rft.issue=6&rft.spage=779&rft_id=info:doi/10.1080%2F17435390.2021.1919330&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1743-5390&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1743-5390&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1743-5390&client=summon |